0001104659-23-094997.txt : 20230824 0001104659-23-094997.hdr.sgml : 20230824 20230824203030 ACCESSION NUMBER: 0001104659-23-094997 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230822 FILED AS OF DATE: 20230824 DATE AS OF CHANGE: 20230824 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Esposito Pamela CENTRAL INDEX KEY: 0001744425 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 231203573 MAIL ADDRESS: STREET 1: C/O REPLIMUNE GROUP, INC. STREET 2: 18 COMMERCE WAY CITY: WOBURN STATE: MA ZIP: 01801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 4 1 tm2324763-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-08-22 0 0001737953 Replimune Group, Inc. REPL 0001744425 Esposito Pamela C/O REPLIMUNE GROUP, INC. 500 UNICORN PARK DRIVE WOBURN MA 01801 0 1 0 0 Chief Business Officer 1 Common Stock 2023-08-22 4 M 0 13600 3.30 A 277036 D Common Stock 2023-08-22 4 M 0 5000 15.50 A 282036 D Common Stock 2023-08-22 4 S 0 18600 20.01 D 263436 D Employee Stock Option (right to buy) 3.30 2023-08-22 4 M 0 13600 0 D 2027-07-26 Common Stock 13600 91691 D Employee Stock Option (right to buy) 15.50 2023-08-22 4 M 0 5000 0 D 2029-04-01 Common Stock 5000 35750 D The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.04. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 497,227 shares of the Issuer's common stock, 378,873 of which are exercisable as of the date hereof. The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. The reporting person was granted an option to purchase 75,750 shares of the Issuer's common stock on April 1, 2019. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. /s/ Shawn Glidden, attorney-in-fact 2023-08-24